Table 3. Patients comorbidities during long-term follow-up.
| Induction therapy | p-value | ||||
|---|---|---|---|---|---|
| No | ATG | Alemtuzumab | |||
| Pre-Tx kidney insufficiency | 12 (7.4%) | 2 (4%) | 6 (2.6%) | 0.810 | |
| Post-Tx kidney insufficiency | 84 (52.2%) | 30 (60%) | 83 (36.6%) | 0.001 | |
| Pre-Tx diabetes | 22 (14%) | 9 (18.8%) | 38 (16.7%) | 0.668 | |
| Post-Tx diabetes | 28 (19.7%) | 16 (35.6%) | 60 (27.1%) | 0.740 | |
| First Infection | < 3 months | 47 (35.3%) | 17 (36.2%) | 47 (21.4%) | 0.001 |
| 3-6months | 29 (21.8%) | 8 (17%) | 39 (17.7%) | ||
| 6–12 months | 27 (20.3%) | 10 (21.3%) | 35 (15.9%) | ||
| >1 year | 21 (15.8%) | 9 (19.1%) | 50 (22.7%) | ||
| Pseudomonas colonization | First year | 25 (17.5%) | 14 (29.8%) | 29 (13.2%) | <0.001 |
| Permanent | 14 (9.8%) | 9 (19.1%) | 25 (11.4%) | ||
| Aspergillus infection | 10 (6.3%) | 7 (14.3%) | 20 (8.8%) | 0.204 | |
| CMV disease | 11 (7.1%) | 3 (11.5%) | 12 (5.3%) | 0.766 | |
| Malignancy | No | 159 (96.4%) | 47 (95.9%) | 224 (97%) | 0.685 |
| PTLD | 3 (1.8%) | 2 (4.1%) | 5 (2.2%) | ||
| Solid tumors | 3 (1.8%) | 0 (0%) | 2 (0.9%) | ||
| Cumulative A score | 1.11±1.3 | 0.73±1.27 | 0.30±0.77 | <0.001 | |
| Cumulative B score | 3.06±2.41 | 3.03±2.36 | 1.40±1.89 | <0.001 | |